INVUITY, INC.
SAN FRANCISCO, CA

Invuity is committed to leveraging intelligent photonics Invuity is committed to leveraging intelligent photonics technology to transform minimal access surgery. Invuity is a medical technology company focused on pioneering the use of advanced photonics to provide surgeons with improved direct visualization of surgical cavities during open minimally invasive and minimal access procedures. Our patented Intelligent Photonics technology enables superior illumination and visualization and is designed to overcome the significant limitations of traditional surgical lighting options in the operating room. A product portfolio that enables clinical and economic outcomes across a broad spectrum of minimally invasive and minimal access procedures. View Our Entire Product Portfolio Vice President of Commercial Marketing & Business Development Joe Guido has served as our Vice President of Commercial Marketing & Business Development since April 2016. He joined the company in February 2016 as Vice President of Business Development. From 2012 to 2016, Mr. Vice President of Product Management and Strategy Steve Annen has served as our Vice President of Product Management and Strategy since April 2016. He joined the company in November 2015 as Senior Director of Product Management and Strategy. Previously, Mr. Gregory T. Lucier has served as a member of our board of directors since October 2014. He is currently Chairman of the Board and Chief Executive Officer at NuVasive, a surgical device company. He has served as a member of the NuVasive Board of Directors since December 2013. Invuity’s patented Intelligent Photonics devices provide direct visualization of the surgical cavity enabling enhanced precision, efficiency and safety. Our Intelligent Photonics technology directs and shapes light into broad, uniform illumination. It converts traditional thermally hot, concentrated light output to thermally cool volumetric illumination throughout the entire surgical cavity. Our technology is integrated into a family of proprietary optical waveguides coupled to a modified fiber optic cable and designed to work with standard xenon and LED light sources used in the operating room. The sophisticated devices integrate a solid-core optical grade polymer, total internal reflection of light waves, light mixing and a complex geometry of refractive microstructures and microlenses to provide direct intracavity illumination and visualization. Our optical waveguides utilize various novel optical methods to mix light, or randomize its reflections, during the total internal reflection transmission process. The design and shape of the optical stem, or area of the waveguide that is between the input of the waveguide and the array of refractive microstructures or microlenses, enhance the mixing of light waves, while maintaining total internal reflection. Our optical waveguides utilize light mixing before extraction to significantly reduce glare and bright spots, leading to a more uniform illumination profile across the surgical target while remaining thermally cool. Invuity Announces Pricing of Public Offering of Common Stock SAN FRANCISCO, March 15, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY) (“Invuity” or the “Company”), a leading medical technology company focused on minimal access surgery, today announced the pricing of its public offering of 6,200,000 shares of its common stock at a price to the public of $3.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 600,000 additional shares of its common stock. William Blair & Company, L.L.C. is acting as the sole book-running manager for the offering. The offering is being made pursuant to an effective shelf registration statement on Form S-3 (No. 333-212395) that was initially filed with the U.S... Invuity Announces Proposed Public Offering of Common Stock SAN FRANCISCO, March 14, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY) ("Invuity" or the "Company"), a leading medical technology company focused on minimal access surgery, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. Invuity expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. Invuity intends to use the net proceeds from the offering for continued expansion of its sales and marketing activities, working capital and other general corporate purposes. William Blair & Company, L.L.C. is acting as the sole book-running manager... Invuity Announces Changes to Executive Leadership Team Scott D. Flora appointed Interim President and Chief Executive Officer Philip Sawyer steps down as President and Chief Executive Officer SAN FRANCISCO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Invuity, Inc. (NASDAQ:IVTY), a leading medical technology company focused on minimal access surgery, today announced that Scott D. Flora, a member of the Company’s Board of Directors since 2017, has been appointed to serve as Interim President and Chief Executive Officer. This appointment follows Philip Sawyer’s resignation as President, Chief Executive Officer and a member of the Company’s Board of Directors. Gregory T. Lucier, Chairman of the Invuity Board of Directors said, “Phil is a truly vis...